Mast Therapeutics, Inc. (MSTX)

[leoncio1]

ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) 20.6% LOWER; announced today that it has signed agreements to purchase shares of its Series F convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19.2 million. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to acquiring and developing additional product candidates, to continue development of its current lead product candidates, and for general corporate purposes